Home ▸ About us ▸ Governance ▸ Leadership Team

Leadership Team

Governance
General Meetings
Board of Directors
Leadership Team
Committees
Auditors
Corporate Governance Reports
Articles of Association

Meet the Leadership Team

Chief Executive Officer

Nicklas Westerholm

Nicklas Westerholm, took office as CEO in June 2017 and has previously worked in the AstraZeneca Group since 1995 in a number of global roles in various business areas, most recently as Vice President Project & Portfolio Management, Cardiovascular and Metabolic Diseases, Global Medicines Development Unit. Prior Nicklas has held positions such as Executive Officer & Vice President Japan Operations, Director Investor Relations, Head of Global API Supply and Head of Development Manufacture.

He has studied Analytical and Organic Chemistry at Stockholm University and Chemical Engineering at KTH, as well as studies at University of Warwick, INSEAD and Harvard Business School.

Number of shares in Egetis: 501,511 shares and 8,360,809 employee stock options.

Chief Financial Officer

Yilmaz Mahshid, PhD

Yilmaz Mahshid, is CFO since 2021. Prior to that he was CEO of Medivir, where he led the development of the company’s strategy, capitalization and struck a worldwide license agreement with a US listed biotech company. Yilmaz has experience from positions as CFO at PledPharma, Investment Manager & Controller in Industrifonden’s Life Science Team and as health care analyst at Pareto Securities and Öhman Fondkommission. His career began as a researcher at the Karolinska Institutet and followed by the same role at the pharmaceutical companies Biolipox and Orexo.

He has a doctorate from the Department of Medical Biochemistry and Biophysics at Karolinska Institutet.

Number of shares in Egetis: 306.249 shares and 3.560.390 employee stock options.

President Egetis North America

Anny Bedard

Anny Bedard, is President of Egetis North America since December 2022. Anny has over 25 years of international experience in both established and entrepreneurial biopharmaceutical companies. She has 15 years of experience in the Rare Disease space. Prior to joining Egetis she served as President of ABio Consulting. Before that she was Vice President, Head of International Business, at Sarepta Therapeutics where she designed and executed Sarepta’s entry into Latin America and Asia Pacific. At Shire, Anny established and led the company’s successful growth in multiple geographies and launched the company’s leading brands in Fabry, Gaucher, Hunter Syndrome and hereditary angioedema.

Anny has a Masters degree in  cellular and molecular biology from Laval University in Quebec, Canada.

Number of shares in Egetis: 42,500 shares and 3,023,966 employee stock options.

Vice President Operations

Katayoun (Katy) Welin-Berger, PhD

Katayoun Welin-Berger took office as Vice President Operations in March 2023. Katy has 30 years of experience in the pharmaceutical, probiotics and dietary supplement industries. She has broad experience from roles with responsibilities within, among other things, product development, CMC documentation, GMP manufacturing, purchasing, outsourcing, supplier management, divestment, supply chain management and product life cycle management. Katy most recently served as Vice President Operations at Calliditas Therapeutics, responsible for designing and managing the supply chains for development candidates and commercial products, and previously held a similar role at BioGaia. Katy began her career in the pharmaceutical industry at AstraZeneca where she held several positions in both R&D and Operations.

Katy obtained a PhD in pharmacy from Uppsala University.

Number of shares in Egetis: 0 shares and 2,859,733 employee stock options.

Vice President Product Strategy & Development

Christian Sonesson, PhD

Christian Sonesson was appointed Vice President Product Strategy & Development in August 2017 following 13 years at AstraZeneca. He has broad experience within drug development, including successfully leading products during Phase 3 (FORXIGA® in type 1 diabetes) and of regulatory submissions and defence, bringing new drug candidates to market in different regions (e.g. FORXIGA® in type 2 diabetes, MOVANTIK®, ONGLYZA®-SAVOR, BRILINTA®-PEGASUS and QTERN®).

Christian has a PhD in Biostatistics from Gothenburg University and an Executive MBA from Stockholm School of Economics.

Number of shares in Egetis: 117,298 shares and 3,560,390 employee stock options.

Vice President Commercial Operations

Henrik Krook, PhD

Henrik Krook, took office as Vice President Commercial Operations in December 2020. He has a broad experience from over 15 years in commercial leadership settings, including both big pharma and biotechs. He has previously held senior corporate and commercial advisory roles for biotech companies such as Affibody and senior managerial positions at e.g. Alexion, Novartis and Roche.

Henrik has a PhD in immunology from Uppsala University and an Executive MBA from Stockholm School of Economics.

Number of shares in Egetis: 459,593 and 3,560,390 employee stock options.

Chief Medical Officer

Tiago Nunes, MD, PhD

Tiago Nunes took office as Chief Medical Officer (CMO) in May 2026. He brings extensive international experience in clinical development and rare diseases, with particular expertise in gastroenterology and hepatology. Prior to joining Egetis, Tiago served as Senior Vice President, Clinical Development at Mirum Pharmaceuticals, where he led the clinical development of Livmarli® and played a key role in its successful approval and launch. Under his leadership, the organization advanced a rare disease portfolio through multiple clinical and regulatory milestones, including label expansions and the progression of innovative clinical programs in cholestatic liver diseases. Prior to Mirum, Tiago held senior clinical development roles at Nestlé Health Science, where he provided medical leadership in gastrointestinal and rare disease drug development.

Tiago earned his medical degree from the Federal University of Rio de Janeiro, Brazil, where he also completed his residency in gastroenterology. He holds a Master’s degree in Biomedicine and a PhD in Medicine from the University of Barcelona, Spain.

Number of shares in Egetis: 0 shares and 880,000 employee stock options.

Vice President, Head of Investor Relations and Business Development

Karl Hård, PhD

Karl Hård, was appointed Vice President, Head of Investor Relations and Business Development, in 2022. Karl has extensive experience from more than 25 years working within research and investor relations at AstraZeneca. He has also worked with investor relations and communication at listed, smaller biotech companies including Kiadis Pharma (Euronext, Amsterdam) and Redx Pharma (AIM, London Stock Exchange). He has also been advisor (via Optimum Strategic Communications) for more than 30 biotech companies in Europe and the USA.

Karl studied biochemistry at University of Helsinki i Finland and has a PhD from Utrecht University in the Netherlands.

Number of shares in Egetis: 297,073 shares and 2,845,158 employee stock options.

Global Head of HR

Nils Hallén

Nils Hallén, has worked as an HR consultant since 2004. His assignment has primarily involved matters relating to staffing, organizational culture and leadership. Besides his consulting work, he has simultaneously held a part-time position at Södertörn University, Stockholm, as a adjunct professor in work and organizational psychology. Prior to that, he has held the position of Head of HR at companies in the travel industry and was CEO at PALAKOM, a training company.

Nils has a law degree from Lund University, where he also studied economics, French and history.

Number of shares in Egetis: 27,396 shares and 1,951,902 employee stock options.

General Counsel & Head of Compliance

Laetitia Szaller

Laetitia Szaller has over 20 years of experience, including 18 in pharmaceuticals and medical devices, leading complex multi-jurisdictional legal matters, M&A, and partnerships.

At Egetis, she heads global legal, compliance, ERM, and ESG, supporting EU and US launch readiness since December 2023. Previously at AM-Pharma, she drove legal operations and corporate development, including IPO readiness and a key Japanese out-licensing deal. At UCB, she served as Associate GC for BD, M&A, and Antitrust, leading major global transactions and earning Top Talent recognition. She also held senior roles at Zoetis (Pfizer), Abbott Vascular, and contributed to EU policymaking via EFPIA. Earlier, she led major global negotiations and restructuring projects at Carlson Rezidor and Wabco.

Laetitia holds qualifications as a lawyer in both the UK and Belgium, showcasing her extensive international experience. Renowned for her insights, she is a regular speaker at various legal conferences, contributing her wealth of knowledge and expertise to the legal community.

Number of shares in Egetis: 48,460 shares and 952,700 employee stock options.

Vice President Regulatory Affairs

Sofie Broberg

Sofie Broberg, Vice President, Regulatory Affairs since September 1, 2026. Sofie has more than 20 years of experience in regulatory affairs from pharmaceutical and life sciences companies, including Sobi, Amgen, Bayer, Diamyd Medical and SDS Life Science. She has extensive expertise in global regulatory strategy, health authority interactions, regulatory submissions, product development and lifecycle management, with particular experience in rare diseases and orphan drug development. Throughout her career, Sofie has led major regulatory submissions and engaged closely with regulatory authorities worldwide. As a regulatory consultant to Egetis Therapeutics, she played a key role in the regulatory strategy and preparation and submission of the Marketing Authorisation Application for Emcitate to the EMA, contributing to its EU approval in February 2025.

Sofie holds an MSc in Biomedicine from Linköping University and has completed additional studies in biomedicine at Karolinska Institutet.

Committees

Explore